;PMID: 2166103
;source_file_952.mrg
;Release 0.9 of PennBioIE
;Funded by NSF ITR EIA-0205448

;0)section:[e:0..43] = [t:0..43]
;1)sentence:[e:49..149] = [t:49..149]
;2)section:[e:153..215] = [t:153..215]
;3)section:[e:219..297] = [t:219..297]
;4)sentence:[e:301..561] = [t:301..561]
;5)sentence:[e:562..908] = [t:562..908]
;6)sentence:[e:909..1082] = [t:909..1082]
;7)sentence:[e:1083..1160] = [t:1083..1160]
;8)sentence:[e:1161..1282] = [t:1161..1282]
;9)sentence:[e:1283..1552] = [t:1283..1552]
;10)section:[e:1556..1600] = [t:1556..1600]

;section 0 Span:0..43
;J Endocrinol Invest. 1990 May;13(5):407-13.
(SEC
  (FRAG (NNP:[0..1] J) (NNP:[2..12] Endocrinol) (NNP:[13..19] Invest)
        (NNP:[19..20] .) (CD:[21..25] 1990) (NNP:[26..29] May)
        (CD:[29..33] ;13-LRB-) (CD:[33..34] 5) (-RRB-:[34..35] -RRB-)
        (CD:[35..39] :407) (HYPH:[39..40] -) (CD:[40..42] 13) (.:[42..43] .)))

;sentence 1 Span:49..149
;Ketoconazole reduces elevated serum levels of 1,25-dihydroxyvitamin D in 
;hypercalcemic sarcoidosis.
;[49..61]:substance:"Ketoconazole"
;[95..118]:substance:"1,25-dihydroxyvitamin D"
(SENT
  (S-HLN
    (NP-SBJ (NN:[49..61] Ketoconazole))
    (VP (VBZ:[62..69] reduces)
      (NP
        (NP (VBN:[70..78] elevated) (NN:[79..84] serum) (NNS:[85..91] levels))
        (PP (IN:[92..94] of)
          (NP (NN:[95..116] 1,25-dihydroxyvitamin) (NN:[117..118] D))))
      (PP (IN:[119..121] in)
        (NP (JJ:[123..136] hypercalcemic) (NN:[137..148] sarcoidosis))))
    (.:[148..149] .)))

;section 2 Span:153..215
;Glass AR, Cerletty JM, Elliott W, Lemann J Jr, Gray RW, Eil C.
(SEC
  (FRAG (NNP:[153..158] Glass) (NNP:[159..161] AR) (,:[161..162] ,)
        (NNP:[163..171] Cerletty) (NNP:[172..174] JM) (,:[174..175] ,)
        (NNP:[176..183] Elliott) (NNP:[184..185] W) (,:[185..186] ,)
        (NNP:[187..193] Lemann) (NNP:[194..195] J) (NNP:[196..198] Jr)
        (,:[198..199] ,) (NNP:[200..204] Gray) (NNP:[205..207] RW)
        (,:[207..208] ,) (NNP:[209..212] Eil) (NNP:[213..215] C.)))

;section 3 Span:219..297
;Department of Medicine, Walter Reed Army Medical Center, Washington, DC
;20307.
(SEC
  (FRAG (NNP:[219..229] Department) (IN:[230..232] of) (NNP:[233..241] Medicine)
        (,:[241..242] ,) (DT:[243..249] Walter) (NNP:[250..254] Reed)
        (NNP:[255..259] Army) (NNP:[260..267] Medical) (NNP:[268..274] Center)
        (,:[274..275] ,) (NNP:[276..286] Washington) (,:[286..287] ,)
        (NNP:[288..290] DC) (CD:[291..296] 20307) (.:[296..297] .)))

;sentence 4 Span:301..561
;The antifungal drug ketoconazole, a cytochrome P450 inhibitor, has been shown
;to  inhibit renal 1,25-dihydroxyvitamin D production in vitro and to lower
;serum  1,25-dihydroxyvitamin D levels in normal subjects and in patients with
;primary  hyperparathyroidism.
;[305..320]:substance:"antifungal drug"
;[321..333]:substance:"ketoconazole"
;[337..352]:cyp450:"cytochrome P450"
;[353..362]:substance:"inhibitor"
;[397..420]:substance:"1,25-dihydroxyvitamin D"
;[461..484]:substance:"1,25-dihydroxyvitamin D"
(SENT
  (S
    (NP-SBJ-1
      (NP
        (NP (DT:[301..304] The)
           (JJ:[305..315] antifungal) (NN:[316..320] drug))
        (NP (NN:[321..333] ketoconazole)))
      (,:[333..334] ,)
      (NP (DT:[335..336] a)
        (NML (NN:[337..347] cytochrome) (NN:[348..352] P450))
        (NN:[353..362] inhibitor)))
    (,:[362..363] ,)
    (VP (VBZ:[364..367] has)
      (VP (VBN:[368..372] been)
        (VP (VBN:[373..378] shown)
          (S
            (NP-SBJ-1 (-NONE-:[378..378] *))
            (VP
              (VP (TO:[379..381] to)
                (VP (VB:[383..390] inhibit)
                  (NP (JJ:[391..396] renal)
                    (NML (NN:[397..418] 1,25-dihydroxyvitamin) (NN:[419..420] D))
                    (NN:[421..431] production))
                  (ADVP (FW:[432..434] in) (FW:[435..440] vitro))))
              (CC:[441..444] and)
              (VP (TO:[445..447] to)
                (VP (VB:[448..453] lower)
                  (NP (NN:[454..459] serum)
                    (NML (NN:[461..482] 1,25-dihydroxyvitamin) (NN:[483..484] D))
                    (NNS:[485..491] levels))
                  (PP-LOC
                    (PP (IN:[492..494] in)
                      (NP (JJ:[495..501] normal) (NNS:[502..510] subjects)))
                    (CC:[511..514] and)
                    (PP (IN:[515..517] in)
                      (NP
                        (NP (NNS:[518..526] patients))
                        (PP (IN:[527..531] with)
                          (NP (JJ:[532..539] primary)
                              (NN:[541..560] hyperparathyroidism)))))))))))))
    (.:[560..561] .)))

;sentence 5 Span:562..908
;To assess the usefulness of this drug in the hypercalcemia  of sarcoidosis, a
;condition thought to result from overproduction of  1,25-dihydroxyvitamin D
;by sarcoid-involved tissues, two men with sarcoidosis,  hypercalcemia, and
;elevated serum levels of 1,25-dihydroxy-vitamin D were given  ketoconazole,
;600-800 mg per day, for four to six days.
;[595..599]:substance:"drug"
;[692..715]:substance:"1,25-dihydroxyvitamin D"
;[816..840]:substance:"1,25-dihydroxy-vitamin D"
;[853..865]:substance:"ketoconazole"
;[867..874]:quantitative-value:"600-800"
;[875..885]:quantitative-units:"mg per day"
;[891..902]:quantitative-value:"four to six"
;[903..907]:quantitative-units:"days"
(SENT
  (S
    (S-PRP
      (NP-SBJ (-NONE-:[562..562] *))
      (VP (TO:[562..564] To)
        (VP (VB:[565..571] assess)
          (NP
            (NP (DT:[572..575] the) (NN:[576..586] usefulness))
            (PP (IN:[587..589] of)
              (NP (DT:[590..594] this) (NN:[595..599] drug))))
          (PP (IN:[600..602] in)
            (NP
              (NP
                (NP (DT:[603..606] the) (NN:[607..620] hypercalcemia))
                (PP (IN:[622..624] of)
                  (NP (NN:[625..636] sarcoidosis))))
              (,:[636..637] ,)
              (NP
                (NP (DT:[638..639] a) (NN:[640..649] condition))
                (VP (VBN:[650..657] thought)
                  (S
                    (NP-SBJ (-NONE-:[657..657] *))
                    (VP (TO:[658..660] to)
                      (VP (VB:[661..667] result)
                        (PP (IN:[668..672] from)
                          (NP
                            (NP (NN:[673..687] overproduction))
                            (PP (IN:[688..690] of)
                              (NP (NN:[692..713] 1,25-dihydroxyvitamin)
                                  (NN:[714..715] D)))
                            (PP (IN:[716..718] by)
                              (NP
                                (ADJP (NN:[719..726] sarcoid)
                                      (HYPH:[726..727] -)
                                      (VBN:[727..735] involved))
                                (NNS:[736..743] tissues)))))))))))))))
    (,:[743..744] ,)
    (NP-SBJ-1
      (NP (CD:[745..748] two) (NNS:[749..752] men))
      (PP (IN:[753..757] with)
        (NP
          (NP (NN:[758..769] sarcoidosis))
          (,:[769..770] ,)
          (NP (NN:[772..785] hypercalcemia))
          (,:[785..786] ,) (CC:[787..790] and)
          (NP
            (NP (VBN:[791..799] elevated) (NN:[800..805] serum)
                (NNS:[806..812] levels))
            (PP (IN:[813..815] of)
              (NP (NN:[816..838] 1,25-dihydroxy-vitamin) (NN:[839..840] D)))))))
    (VP (VBD:[841..845] were)
      (VP (VBN:[846..851] given)
        (NP-1 (-NONE-:[851..851] *))
        (NP
          (NP (NN:[853..865] ketoconazole))
          (,:[865..866] ,)
          (NP
            (NP
              (QP (CD:[867..870] 600) (HYPH:[870..871] -) (CD:[871..874] 800))
              (NN:[875..877] mg))
            (PP (IN:[878..881] per)
              (NP (NN:[882..885] day)))))
        (,:[885..886] ,)
        (PP-TMP (IN:[887..890] for)
          (NP
            (QP (CD:[891..895] four) (TO:[896..898] to) (CD:[899..902] six))
            (NNS:[903..907] days)))))
    (.:[907..908] .)))

;sentence 6 Span:909..1082
;Serum  1,25-dihydroxyvitamin D levels were markedly reduced (by approximately
;40%) in  both patients during ketoconazole administration, but serum calcium
;was not  affected.
;[916..939]:substance:"1,25-dihydroxyvitamin D"
;[987..990]:quantitative-value:"40%"
;[1017..1029]:substance:"ketoconazole"
;[1056..1063]:substance:"calcium"
(SENT
  (S
    (S
      (NP-SBJ (NN:[909..914] Serum)
        (NML (NN:[916..937] 1,25-dihydroxyvitamin) (NN:[938..939] D))
        (NNS:[940..946] levels))
      (VP (VBD:[947..951] were)
        (ADVP (RB:[952..960] markedly))
        (VP (VBN:[961..968] reduced)
          (PRN (-LRB-:[969..970] -LRB-)
            (PP-EXT (IN:[970..972] by)
              (NP
                (QP (RB:[973..986] approximately) (CD:[987..989] 40))
                (NN:[989..990] %)))
            (-RRB-:[990..991] -RRB-))
          (PP-LOC (IN:[992..994] in)
            (NP (DT:[996..1000] both) (NNS:[1001..1009] patients)))
          (PP-TMP (IN:[1010..1016] during)
            (NP (NN:[1017..1029] ketoconazole) (NN:[1030..1044] administration))))))
    (,:[1044..1045] ,) (CC:[1046..1049] but)
    (S
      (NP-SBJ-1 (NN:[1050..1055] serum) (NN:[1056..1063] calcium))
      (VP (VBD:[1064..1067] was) (RB:[1068..1071] not)
        (VP (VBN:[1073..1081] affected)
          (NP-1 (-NONE-:[1081..1081] *)))))
    (.:[1081..1082] .)))

;sentence 7 Span:1083..1160
;In both patients, renal function deteriorated during ketoconazole 
;treatment.
;[1136..1148]:substance:"ketoconazole"
(SENT
  (S
    (PP-LOC (IN:[1083..1085] In)
      (NP (DT:[1086..1090] both) (NNS:[1091..1099] patients)))
    (,:[1099..1100] ,)
    (NP-SBJ (JJ:[1101..1106] renal) (NN:[1107..1115] function))
    (VP (VBD:[1116..1128] deteriorated)
      (PP-TMP (IN:[1129..1135] during)
        (NP (NN:[1136..1148] ketoconazole) (NN:[1150..1159] treatment))))
    (.:[1159..1160] .)))

;sentence 8 Span:1161..1282
;We conclude that ketoconazole administration can lower the elevated  serum
;1,25-dihydroxyvitamin D levels in sarcoidosis.
;[1178..1190]:substance:"ketoconazole"
;[1236..1259]:substance:"1,25-dihydroxyvitamin D"
(SENT
  (S
    (NP-SBJ (PRP:[1161..1163] We))
    (VP (VBP:[1164..1172] conclude)
      (SBAR (IN:[1173..1177] that)
        (S
          (NP-SBJ (NN:[1178..1190] ketoconazole)
                  (NN:[1191..1205] administration))
          (VP (MD:[1206..1209] can)
            (VP (VB:[1210..1215] lower)
              (NP (DT:[1216..1219] the) (VBN:[1220..1228] elevated)
                  (NN:[1230..1235] serum)
                (NML (NN:[1236..1257] 1,25-dihydroxyvitamin) (NN:[1258..1259] D))
                (NNS:[1260..1266] levels))
              (PP (IN:[1267..1269] in)
                (NP (NN:[1270..1281] sarcoidosis))))))))
    (.:[1281..1282] .)))

;sentence 9 Span:1283..1552
;However, deterioration of  renal function during ketoconazole administration
;as well as failure of  hypercalcemia to be affected during short-term
;ketoconazole treatment suggest  that this drug might not be appropriate for
;acute treatment of hypercalcemic  sarcoidosis.
;[1332..1344]:substance:"ketoconazole"
;[1430..1442]:substance:"ketoconazole"
;[1472..1476]:substance:"drug"
(SENT
  (S
    (ADVP (RB:[1283..1290] However))
    (,:[1290..1291] ,)
    (NP-SBJ
      (NP
        (NP (NN:[1292..1305] deterioration))
        (PP (IN:[1306..1308] of)
          (NP (JJ:[1310..1315] renal) (NN:[1316..1324] function)))
        (PP (IN:[1325..1331] during)
          (NP (NN:[1332..1344] ketoconazole) (NN:[1345..1359] administration))))
      (CONJP (RB:[1360..1362] as) (RB:[1363..1367] well) (IN:[1368..1370] as))
      (NP
        (NP (NN:[1371..1378] failure)
          (S-2 (-NONE-:[1378..1378] *ICH*)))
        (PP (IN:[1379..1381] of)
          (NP (NN:[1383..1396] hypercalcemia)))
        (S-2
          (NP-SBJ-1 (-NONE-:[1396..1396] *))
          (VP (TO:[1397..1399] to)
            (VP (VB:[1400..1402] be)
              (VP (VBN:[1403..1411] affected)
                (NP-1 (-NONE-:[1411..1411] *))
                (PP (IN:[1412..1418] during)
                  (NP
                    (NML (JJ:[1419..1424] short) (HYPH:[1424..1425] -)
                         (NN:[1425..1429] term))
                    (NN:[1430..1442] ketoconazole) (NN:[1443..1452] treatment)))))))))
    (VP (VBP:[1453..1460] suggest)
      (SBAR (IN:[1462..1466] that)
        (S
          (NP-SBJ (DT:[1467..1471] this) (NN:[1472..1476] drug))
          (VP (MD:[1477..1482] might) (RB:[1483..1486] not)
            (VP (VB:[1487..1489] be)
              (ADJP-PRD (JJ:[1490..1501] appropriate)
                (PP (IN:[1502..1505] for)
                  (NP
                    (NP (JJ:[1506..1511] acute) (NN:[1512..1521] treatment))
                    (PP (IN:[1522..1524] of)
                      (NP (JJ:[1525..1538] hypercalcemic)
                          (NN:[1540..1551] sarcoidosis)))))))))))
    (.:[1551..1552] .)))

;section 10 Span:1556..1600
;PMID: 2166103 [PubMed - indexed for MEDLINE]
(SEC
  (FRAG (NNP:[1556..1560] PMID) (::[1560..1561] :) (CD:[1562..1569] 2166103)
        (IN:[1570..1571] -LSB-) (NNP:[1571..1577] PubMed) (HYPH:[1578..1579] -)
        (JJ:[1580..1587] indexed) (IN:[1588..1591] for)
        (NNP:[1592..1600] MEDLINE-RSB-)))
